Key result
Agonistic AT1R and ETAR autoantibodies linked to endothelial dysfunction, microvascular injury, and adverse cardiac remodeling.
Why the study?
Autoantibodies targeting AT1R and ETAR may contribute to cardiovascular disease, but their mechanistic framework, clinical evidence, and translational validation require critical appraisal.
Agonistic autoantibodies targeting AT1R and ETAR represent a potential novel mechanism for microvascular injury and adverse remodeling in cardiovascular disease, warranting further translational validation.
May refine post-STEMI risk stratification; leaves open causality and therapeutic targeting pending randomized validation.
Autoimmune mechanisms are increasingly recognized as contributors to cardiovascular disease, extending beyond the traditional view of autoantibodies as passive markers of tissue injury. Among functional autoantibodies, those targeting the angiotensin II type 1 receptor (AT1R) and the endothelin-1 type A receptor (ETAR) represent a distinctive class capable of inducing sustained, ligand-independent activation of vasoactive G protein–coupled receptors. Emerging experimental and translational evidence suggests that these agonistic autoantibodies may contribute to endothelial dysfunction, microvascular injury, and adverse cardiac remodelling through persistent receptor stimulation and downstream pro-inflammatory and pro-fibrotic signalling. Clinical observations, particularly in reperfused ST-elevation myocardial infarction, support an association with impaired myocardial reperfusion and unfavourable outcomes, although causality remains unproven. In this perspective, we aim to delineate the mechanistic framework of AT1R- and ETAR-targeting agonistic autoantibodies, critically appraise the available clinical evidence, and outline key priorities for their translational validation in cardiovascular disease. Further investigation is required to determine their potential role in risk stratification and as therapeutic targets. Integrating immunological markers into cardiovascular research may provide new avenues for translational advancement, while necessitating rigorous validation in well-designed clinical studies.
No takes yet. Share an insight, caveat, or question.
Tona et al. (2026) conducted a review in Cardiovascular disease. Agonistic autoantibodies targeting AT1R and ETAR was evaluated. Agonistic autoantibodies targeting AT1R and ETAR may contribute to endothelial dysfunction, microvascular injury, and adverse cardiac remodelling, although causality remains unproven.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: